Outlook Therapeutics reveals validation of Marketing Authorization Application by European Medicines Agency for ONS-5010
The company said the submission follows the FDA acceptance of the ONS-5010 BLA for the treatment of wet AMD, with a PDUFA date of August 29, 2023.
Study reveals the signaling cascade behind retina regeneration in zebrafish
According to a team of investigators from the University of Michigan, the findings could help inform treatments for blindness in humans.
Investigators focus on finding cure for AMD
Scientists from the Clear Vision Research Lab at The Australian National University and the Korean biotech company MDimune Inc. hope to turn recent research milestones into potential treatments for AMD.
Researchers offer expanded knowledge about development, progression of ROP
Retinopathy of prematurity is thought to be a two-stage disorder that begins with the arrested development of the retinal vessels in preterm babies when exposed to high oxygen levels at birth.
Emmes launches cell and gene therapy center
The Cell and Gene Therapy Center will combine a team of 100 researchers to capitalize on the company’s 35 years of cell and gene therapy experience.
Congress reaches compromise on Medicare reimbursement cuts for physicians
On Tuesday, lawmakers unveiled the $1.7 trillion proposed spending package needed to avert a government shutdown by Friday if both chambers can pass the measure this week.
Innovation Pharmaceuticals details in vivo antifungal data showing brilacidin’s potential for treating fungal keratitis
Previous research conducted primarily by scientists at the University of São Paulo, Brazil, showed brilacidin can potentiate several marketed antifungals, including caspofungin, voriconazole and posaconazole.
Pixium Vision finishes implantations in its European PRIMAvera pivotal trial in atrophic dry AMD
The company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.
STAAR Surgical CEO Caren Mason to retire; Tom Frinzi appointed new CEO
STAAR Surgical President and CEO Caren Mason will be retiring December 31, and ophthalmic industry executive Thomas “Tom” G. Frinzi has been tapped as her replacement.
Rezolute kicking off phase 2 study of RZ402 in patients diagnosed with diabetic macular edema
Company officials point out that RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye.
AI-diagnostics startup Altris AI raises $1 million to prevent blindness
Runa Capital-led funding will help scale the AI-powered eye pathology detection solution.
EyeCon 2022: Ophthalmology Times co-chairs discuss highlights of Day 1
Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.
AXIM Biotechnologies develops novel dual IgE/MMP-9 rapid ophthalmological diagnostic test; files provisional patent
The test is slated for further clinical development in the first quarter of 2023 and, once FDA approved, will be added to the company's catalog of ophthalmological diagnostic tools available to clinicians throughout North America.
NovaSight introducing CureSight to U.S. market
The company is poised to roll out its eye-tracking amblyopia treatment to the U.S. market.
Helping patients navigate telehealth video visits benefits practice
According to the study, attendance improved by 9% and the return on investment totaled $11,387 over a 12-week period.
Oxurion announces the continuation of KALAHARI Phase 2, Part B study in diabetic macular edema following interim analysis
The IDMC recommended continuation of the study based upon the outcome of the futility analysis.
Harrow to acquire U.S. rights to Novartis drugs
Harrow Health Inc. announced it has agreed to purchase the exclusive U.S. commercial rights to 5 ophthalmic drugs from Novartis AG for up to $175 million, the company announced today.
Eversight, Department of Health – Abu Dhabi partner to establish UAE’s first eye and tissue bank
The partnership was formalized at the recent International Conference for Initiatives on Organ and Tissue Donation and Transplantation in Abu Dhabi.
CORD files for premarket approval with FDA for the SC9 IOL for cataract surgery
Titan Pharmaceuticals announces licensing agreement with Ocular Therapeutix
Under the terms of the agreement, Ocular will pay Titan an upfront licensing fee with the potential for additional payments upon reaching certain milestones.
Azura Ophthalmics presents positive results from Phase 2b clinical trial of AZR-MD-001
AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.
Aviceda announces completion of key IND toxicity milestone with positive safety profile in non-human primates
The results represent a major step towards first in-human clinical studies for this program - the first potential therapy for patients with geographic atrophy secondary to AMD that addresses the underlying causes of the disease.
UC Davis opens new state-of-the-art eye care facility
The Ernest E. Tschannen Eye Institute is dedicated to eye care and sight restoration through technology, pioneering research and eye care clinicians.
Ocuphire Pharma submits New Drug Application to FDA for Nyxol eye drops for reversal of mydriasis
According to the company, the NDA is supported by positive phase data demonstrating the rapid reversal of dilated eyes and favorable safety profile in pediatric and adult subjects.
New potential mechanism for vision loss discovered
Researchers from the Deutsches Zentrum für Neurodegenerative Erkrankungen and the Center for Regenerative Therapies Dresden at TU Dresden have found that visual cells in the human retina may not simply die in some diseases, but are mechanically transported out of the retina beforehand.
Retinal cells may have potential to protect themselves from diabetic retinopathy
According to researchers, cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.
New genetic mutation behind childhood glaucoma identified
Researchers found through DNA sequencing and confirmed in further testing that a genetic mutation in the THBS1 gene led to the development of severe childhood glaucoma. The discovery may improve disease screening and personalize treatments.
SparingVision’s lead asset SPVN06 clears IND application in US for treatment of retinitis pigmentosa
SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by IRDs and dry age-related macular degeneration (AMD), regardless of their genetic background.
Opus Genetics receives FDA Clearance of IND application for OPGx-001 for treatment of retinal disease LCA5
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in the LCA5 gene, which causes one of the most severe forms of early-onset blinding disease Leber congenital amaurosis.
Study: One of two macular degeneration drugs outperforming other at weaning patients off treatment at one year
Aflibercept and bevacizumab are the two most frequently used therapies for the treatment of wet AMD.
2 Clarke Drive Cranbury, NJ 08512